Predicting Pneumonia in Chronic Obstructive Pulmonary Disease. Have We Unraveled the Network of Risks?
作者信息
Dransfield Mark T, Singh Dave
机构信息
Division of Pulmonary, Allergy, and Critical CareUniversity of Alabama at BirminghamBirmingham, Alabama.
Birmingham VA Medical CenterBirmingham, Alabama.
出版信息
Am J Respir Crit Care Med. 2020 May 1;201(9):1026-1027. doi: 10.1164/rccm.202001-0132ED.
Abstract
摘要
相似文献
1
Predicting Pneumonia in Chronic Obstructive Pulmonary Disease. Have We Unraveled the Network of Risks?预测慢性阻塞性肺疾病中的肺炎。我们是否理清了风险网络？
Am J Respir Crit Care Med. 2020 May 1;201(9):1026-1027. doi: 10.1164/rccm.202001-0132ED.
2
Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis.吸入性类固醇、循环嗜酸性粒细胞、慢性气道感染与慢性阻塞性肺疾病肺炎风险：网络分析。
Am J Respir Crit Care Med. 2020 May 1;201(9):1078-1085. doi: 10.1164/rccm.201908-1550OC.
3
Blood eosinophils in COPD and the future risk of pneumonia.慢性阻塞性肺疾病中的血液嗜酸性粒细胞与未来肺炎风险
Eur Respir J. 2018 Jul 27;52(1). doi: 10.1183/13993003.00981-2018. Print 2018 Jul.
4
Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.血嗜酸性粒细胞计数与慢性阻塞性肺疾病患者肺炎风险：一项基于患者的荟萃分析。
Lancet Respir Med. 2016 Sep;4(9):731-741. doi: 10.1016/S2213-2600(16)30148-5. Epub 2016 Jul 23.
5
Comparing severity scores in exacerbations of chronic obstructive pulmonary disease.慢性阻塞性肺疾病急性加重期严重程度评分的比较
Clin Respir J. 2018 Dec;12(12):2668-2675. doi: 10.1111/crj.12973.
6
Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease. Blood Eosinophils Gain Momentum.预测慢性阻塞性肺疾病中皮质类固醇的反应。血液嗜酸性粒细胞势头渐起。
Am J Respir Crit Care Med. 2017 Nov 1;196(9):1098-1100. doi: 10.1164/rccm.201703-0592ED.
7
Childhood pneumonia increases risk for chronic obstructive pulmonary disease: the COPDGene study.儿童肺炎增加慢性阻塞性肺疾病风险：慢性阻塞性肺疾病基因研究
Respir Res. 2015 Sep 21;16(1):115. doi: 10.1186/s12931-015-0273-8.
8
Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease.嗜酸性粒细胞在慢性阻塞性肺疾病气道炎症中的作用。
Int J Chron Obstruct Pulmon Dis. 2018 Jan 17;13:335-349. doi: 10.2147/COPD.S152291. eCollection 2018.
9
[Severe pneumonia due to cytomegalovirus in chronic obstructive pulmonary disease].慢性阻塞性肺疾病合并巨细胞病毒所致重症肺炎
Rev Mal Respir. 2014 May;31(5):435-8. doi: 10.1016/j.rmr.2013.09.013. Epub 2013 Dec 2.
10
Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies.大环内酯类抗生素治疗下呼吸道感染后心血管事件的发生：两项前瞻性队列研究分析。
BMJ. 2013 Mar 20;346:f1235. doi: 10.1136/bmj.f1235.
引用本文的文献
1
The Burden of COPD with Type 2 Inflammation in North-West Continental Europe.西北欧地区2型炎症相关慢性阻塞性肺疾病的负担
Int J Chron Obstruct Pulmon Dis. 2025 Aug 7;20:2767-2785. doi: 10.2147/COPD.S523371. eCollection 2025.
2
Risk factors for SARS-CoV-2 pneumonia among renal transplant recipients in Omicron pandemic-a prospective cohort study.奥密克戎大流行期间肾移植受者感染新型冠状病毒肺炎的危险因素——一项前瞻性队列研究
Virol J. 2024 Dec 4;21(1):315. doi: 10.1186/s12985-024-02591-9.
3
Association of blood eosinophils with corticosteroid treatment failure stratified by smoking status among inpatients with AECOPD.吸烟状况分层的 AECOPD 住院患者中血嗜酸性粒细胞与皮质类固醇治疗失败的相关性。
BMJ Open Respir Res. 2024 Apr 12;11(1):e001634. doi: 10.1136/bmjresp-2023-001634.
4
Using Blood Eosinophil Count as a Biomarker to Guide Corticosteroid Treatment for Chronic Obstructive Pulmonary Disease.以血嗜酸性粒细胞计数作为生物标志物指导慢性阻塞性肺疾病的糖皮质激素治疗
Diagnostics (Basel). 2021 Feb 3;11(2):236. doi: 10.3390/diagnostics11020236.
5
The relationship between airway immunoglobulin activity and eosinophils in COPD.COPD 患者气道免疫球蛋白活性与嗜酸性粒细胞的关系。
J Cell Mol Med. 2021 Feb;25(4):2203-2212. doi: 10.1111/jcmm.16206. Epub 2020 Dec 27.
6
Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects.慢性阻塞性肺疾病中的血液嗜酸性粒细胞计数：吸入性糖皮质激素疗效的生物标志物
Tuberc Respir Dis (Seoul). 2020 Jul;83(3):185-194. doi: 10.4046/trd.2020.0026. Epub 2020 Apr 29.
本文引用的文献
1
Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis.吸入性类固醇、循环嗜酸性粒细胞、慢性气道感染与慢性阻塞性肺疾病肺炎风险：网络分析。
Am J Respir Crit Care Med. 2020 May 1;201(9):1078-1085. doi: 10.1164/rccm.201908-1550OC.
2
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.血液嗜酸性粒细胞与慢性阻塞性肺疾病三联和双联治疗反应：IMPACT 试验分析。
Lancet Respir Med. 2019 Sep;7(9):745-756. doi: 10.1016/S2213-2600(19)30190-0. Epub 2019 Jul 4.
3
Sputum is reduced in COPD following treatment with benralizumab.贝那鲁肽治疗后 COPD 患者痰液减少。
Int J Chron Obstruct Pulmon Dis. 2019 Jun 5;14:1177-1185. doi: 10.2147/COPD.S198302. eCollection 2019.
4
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.全球慢性阻塞性肺疾病诊断、管理和预防策略：GOLD 科学委员会报告 2019.
Eur Respir J. 2019 May 18;53(5). doi: 10.1183/13993003.00164-2019. Print 2019 May.
5
Inhaled corticosteroids in COPD: friend or foe?COPD 患者的吸入性皮质类固醇：是敌是友？
Eur Respir J. 2018 Dec 13;52(6). doi: 10.1183/13993003.01219-2018. Print 2018 Dec.
6
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.特布他林、布地奈德/福莫特罗和茚达特罗/格隆溴铵治疗慢性阻塞性肺疾病（TRIBUTE）的随机对照双盲平行分组研究
Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9.
7
Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease. Blood Eosinophils Gain Momentum.预测慢性阻塞性肺疾病中皮质类固醇的反应。血液嗜酸性粒细胞势头渐起。
Am J Respir Crit Care Med. 2017 Nov 1;196(9):1098-1100. doi: 10.1164/rccm.201703-0592ED.
8
Blood and sputum eosinophils in COPD; relationship with bacterial load.慢性阻塞性肺疾病中的血液和痰液嗜酸性粒细胞；与细菌载量的关系。
Respir Res. 2017 May 8;18(1):88. doi: 10.1186/s12931-017-0570-5.
9
Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.血嗜酸性粒细胞计数与慢性阻塞性肺疾病患者肺炎风险：一项基于患者的荟萃分析。
Lancet Respir Med. 2016 Sep;4(9):731-741. doi: 10.1016/S2213-2600(16)30148-5. Epub 2016 Jul 23.
10
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.氟替卡松酯和维兰特罗与心血管风险升高的慢性阻塞性肺疾病患者的生存关系（SUMMIT）：一项双盲随机对照试验。
Lancet. 2016 Apr 30;387(10030):1817-26. doi: 10.1016/S0140-6736(16)30069-1. Epub 2016 Apr 28.
Zotero 插件